| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
97,400,000 |
| Market
Cap: |
20.77(B) |
| Last
Volume: |
542,269 |
Avg
Vol: |
762,833 |
| 52
Week Range: |
$197.69 - $241.33 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 274 |
| Guru Rank Value : 4.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Laboratory Corporation of America Holdings is a life sciences company that provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. Co. reports its business in two segments, LabCorp Diagnostics (Dx) and Labcorp Drug Development (DD). Dx is an independent clinical laboratory business. It provides a menu of requested and specialty testing through a network of primary and specialty laboratories across the U.S. DD provides drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
44 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10,251 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
56,748 |
58,821 |
69,833 |
140,059 |
| Total Sell Value |
$12,249,331 |
$12,694,711 |
$15,061,286 |
$31,763,598 |
| Total People Sold |
7 |
7 |
8 |
8 |
| Total Sell Transactions |
10 |
14 |
18 |
28 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  King David P |
Director |
• • – |
2020-02-12 |
4 |
D |
$187.51 |
$615,033 |
D/D |
(3,280) |
313,392 |
|
- |
|
| King David P |
Director |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,749 |
315,286 |
|
- |
|
| Kirchgraber Paul R |
CEO, Covance Drug Development |
• • – |
2020-02-12 |
4 |
D |
$187.51 |
$29,814 |
D/D |
(159) |
5,061 |
|
- |
|
| Kirchgraber Paul R |
CEO, Covance Drug Development |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
579 |
5,149 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,227 |
6,322 |
|
- |
|
| Neupert Peter M |
Director |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,227 |
9,996 |
|
- |
|
| Kong Garheng |
Director |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,227 |
8,452 |
|
- |
|
| Gilliland Dwight Gary |
Director |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,227 |
5,766 |
|
- |
|
| Parham Richelle P |
Director |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,227 |
5,088 |
|
- |
|
| Schroeder Mark S |
EVP, President-Diagnostics Lab |
• • – |
2020-02-10 |
4 |
AS |
$181.99 |
$19,655 |
D/D |
(108) |
300 |
|
-11% |
|
| Van Der Vaart Sandra D |
SVP, Global General Counsel |
• • – |
2020-02-10 |
4 |
AS |
$181.99 |
$24,205 |
D/D |
(133) |
2,529 |
|
-11% |
|
| Schroeder Mark S |
EVP, President-Diagnostics Lab |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$14,951 |
D/D |
(82) |
408 |
|
- |
|
| Schroeder Mark S |
EVP, President-Diagnostics Lab |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
297 |
490 |
|
- |
|
| Van Der Vaart Sandra D |
SVP, Global General Counsel |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$18,415 |
D/D |
(101) |
2,662 |
|
- |
|
| Van Der Vaart Sandra D |
SVP, Global General Counsel |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
367 |
2,763 |
|
- |
|
| Kirchgraber Paul R |
CEO, Covance Drug Development |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$18,780 |
D/D |
(103) |
4,641 |
|
- |
|
| Kirchgraber Paul R |
CEO, Covance Drug Development |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
337 |
4,744 |
|
- |
|
| Eisenberg Glenn A |
Chief Financial Officer, EVP |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$53,787 |
D/D |
(295) |
17,758 |
|
- |
|
| Eisenberg Glenn A |
Chief Financial Officer, EVP |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
994 |
18,053 |
|
- |
|
| King David P |
Director |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$228,277 |
D/D |
(1,252) |
308,923 |
|
- |
|
| King David P |
Director |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,220 |
310,175 |
|
- |
|
| Berberian Lance |
SVP, Chief Information Officer |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$18,780 |
D/D |
(103) |
6,291 |
|
- |
|
| Berberian Lance |
SVP, Chief Information Officer |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
297 |
6,394 |
|
- |
|
| Belingard Jean Luc |
Director |
• • – |
2019-12-04 |
4 |
D |
$171.82 |
$56,185 |
D/D |
(327) |
36,957 |
|
- |
|
| Belingard Jean Luc |
Director |
• • – |
2019-12-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,271 |
37,284 |
|
- |
|
933 Records found
|
|
Page 19 of 38 |
|
|
2.01 (0.95%) 
